Zydus Lifesciences Limited

957.4

INR
-6.35(-0.66%)
As of November 14, 2024 10:00:00 AM

Zydus Lifesciences Limited Share Price Information

24 hour Low and High

Low: 954
High: 975.4

All time High

1300.90

Price Change 1h

+₹-8.35 +-0.86%

Price Change 1d

+₹-8.35 +-0.86%

Price Change 1w

+₹-12.95 +-1.33%

Zydus Lifesciences Limited Market Information

Exchange

NSE

Market Cap

100769.81 Cr

About Zydus Lifesciences Limited Share

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

26921

CEO

Mr. Punit Patel

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • Analysts wary of Zydus Life's US sales post FY25, valuations; stock down 5%
  • India's Zydus Life posts Q2 profit rise on steady US demand
  • Stocks To Watch: ONGC, Hindalco, RVNL, IRFC, Sagility India, Zydus Life, Nykaa
  • Zydus Lifesciences shares fall 6%, brokerages neutral on Sterling Biotech deal
  • Zydus Lifesciences stock slides 16% from recent peak, Elara Capital sees a buy opportunity; raises target price | Stock Market News

FAQs

Zydus Lifesciences Limited

957.4

INR
-6.35(-0.66%)
As of November 14, 2024 10:00:00 AM

Zydus Lifesciences Limited Share Price Information

24 hour Low and High

Low: 954
High: 975.4

All time High

1300.90

Price Change 1h

+₹-8.35 +-0.86%

Price Change 1d

+₹-8.35 +-0.86%

Price Change 1w

+₹-12.95 +-1.33%

Zydus Lifesciences Limited Market Information

Exchange

NSE

Market Cap

100769.81 Cr

About Zydus Lifesciences Limited Share

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

26921

CEO

Mr. Punit Patel

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • Analysts wary of Zydus Life's US sales post FY25, valuations; stock down 5%
  • India's Zydus Life posts Q2 profit rise on steady US demand
  • Stocks To Watch: ONGC, Hindalco, RVNL, IRFC, Sagility India, Zydus Life, Nykaa
  • Zydus Lifesciences shares fall 6%, brokerages neutral on Sterling Biotech deal
  • Zydus Lifesciences stock slides 16% from recent peak, Elara Capital sees a buy opportunity; raises target price | Stock Market News

FAQs